| Literature DB >> 28513576 |
Enea Gino Di Domenico1, Ilaria Farulla2, Grazia Prignano3, Maria Teresa Gallo4, Matteo Vespaziani5, Ilaria Cavallo6, Isabella Sperduti7, Martina Pontone8, Valentina Bordignon9, Laura Cilli10, Alessandra De Santis11, Fabiola Di Salvo12, Fulvia Pimpinelli13, Ilaria Lesnoni La Parola14, Luigi Toma15, Fabrizio Ensoli16.
Abstract
Bacterial biofilm is a major factor in delayed wound healing and high levels of biofilm production have been repeatedly described in multidrug resistant organisms (MDROs). Nevertheless, a quantitative correlation between biofilm production and the profile of antimicrobial drug resistance in delayed wound healing remains to be determined. Microbial identification, antibiotic susceptibility and biofilm production were assessed in 135 clinical isolates from 87 patients. Gram-negative bacteria were the most represented microorganisms (60.8%) with MDROs accounting for 31.8% of the total isolates. Assessment of biofilm production revealed that 80% of the strains were able to form biofilm. A comparable level of biofilm production was found with both MDRO and not-MDRO with no significant differences between groups. All the methicillin-resistant Staphylococcus aureus (MRSA) and 80% of Pseudomonas aeruginosa MDR strains were found as moderate/high biofilm producers. Conversely, less than 17% of Klebsiella pneumoniae extended-spectrum beta-lactamase (ESBL), Escherichia coli-ESBL and Acinetobacter baumannii were moderate/high biofilm producers. Notably, those strains classified as non-biofilm producers, were always associated with biofilm producer bacteria in polymicrobial colonization. This study shows that biofilm producers were present in all chronic skin ulcers, suggesting that biofilm represents a key virulence determinant in promoting bacterial persistence and chronicity of ulcerative lesions independently from the MDRO phenotype.Entities:
Keywords: Acinetobacter baumannii; ESBL; Escherichia coli; Klebsiella pneumoniae; MDRO; MRSA; Pseudomonas aeruginosa; biofilm; skin ulcer; wound
Mesh:
Substances:
Year: 2017 PMID: 28513576 PMCID: PMC5454986 DOI: 10.3390/ijms18051077
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Bacterial isolates from patients with colonized skin ulcers: Staphylococcus aureus, Pseudomonas aeruginosa, Proteus mirabilis, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumonia, Enterococcus faecalis, Enterobacter cloacae, Stenotrophomonas maltophilia, Citrobacter freundii, Morganella morganii, Streptococcus agalactiae, Klebsiella oxytoca, Enterobacter aerogenes, Proteus vulgaris and Serratia marcescens. Data in percentage. In brackets, the absolute occurrence of different bacterial species. Blue = Gram-positive; red = Gram-negative.
Antibiotic resistance pattern of Gram-negative bacilli not MDR (% of resistance). n represents the number of samples. Blank: data not available.
| Drug | |||||||
|---|---|---|---|---|---|---|---|
| Amikacin | 0 | 0 | 43.8 | 0 | 0 | 0 | 0 |
| Gentamicin | 0 | 0 | 75 | 0 | 0 | 50 | 14.3 |
| Tobramycin | 50 | 11.1 | |||||
| Ertapenem | 0 | 0 | 0 | 0 | |||
| Imipenem | 0 | 0 | 0 | 0 | 0 | ||
| Meropenem | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cefepime | 0 | 0 | 25 | 0 | 0 | 0 | 7.1 |
| Cefotaxime | 0 | 0 | 62.5 | 0 | 0 | 100 | |
| Ceftazidime | 0 | 0 | 62.5 | 0 | 0 | 100 | 0 |
| Nitrofurantoin | 0 | 100 | |||||
| Amoxicillin/clavulanic acid | 22.2 | 0 | 100 | 100 | 100 | ||
| Piperacillin/Tazobactam | 0 | 0 | 0 | ||||
| Colistin | 0 | 0 | 100 | 0 | 100 | 7.1 | |
| Ciprofloxacin | 22.2 | 0 | 68.8 | 0 | 0 | 66.6 | 14.3 |
| Levofloxacin | 50 | ||||||
| Trimethoprim/sulfamethoxazole | 55.5 | 0 | 75 | 20 | 0 | 50 | 100 |
| Tigecycline | 100 | 100 |
Antibiotic resistance pattern of Gram-positive cocci not MDR (% of resistance). MSSA = methicillin-sensitive S. aureus. n represents the number of samples. Blank: data not available.
| Drug | MSSA | ||
|---|---|---|---|
| Gentamicin | 18.2 | ||
| Gentamicin High Level Resistance | 40 | ||
| Streptomycin High Level Resistance | 80 | ||
| Imipenem | 0 | ||
| Teicoplanin | 4.3 | 0 | 0 |
| Vancomycin | 0 | 0 | 0 |
| Clindamycin | 26.1 | 100 | 100 |
| Daptomycin | 0 | ||
| Erythromycin | 31.8 | 66.7 | |
| Nitrofurantoin | 0 | 0 | |
| Linezolid | 0 | 0 | 0 |
| Ampicillin/sulbactam | 0 | ||
| Benzylpenicillin | 69.6 | 0 | |
| Oxacillin | 0 | ||
| Levofloxacin | 8.7 | 50 | 0 |
| Moxifloxacin | 0 | ||
| Trimethoprim/sulfamethoxazole | 0 | 100 | 0 |
| Tetracyclin | 8.7 | 100 | |
| Fusidic Acid | 0 | ||
| Tigecycline | 0 | 0 | 0 |
Figure 2Quantity of not-MDRO (red) compared to its respective counterparts MDRO (blue): MRSA versus MSSA, MDRPA versus P. aeruginosa, ESBL-producing E. coli and K. pneumoniae versus E. coli and K. pneumoniae, respectively, and A. baumannii.
Antibiotic resistance pattern of MDROs (% of resistance). Blank: data not available. MRSA = methicillin-resistant; ESBL = positive to the production of extended-spectrum beta-lactamase; MDRPA = multidrug resistant P. aeruginosa. n represents the number of samples.
| Drug | MRSA | ||||
|---|---|---|---|---|---|
| Amikacin | 16.7 | 33.3 | 80 | ||
| Gentamicin | 50 | 75 | 100 | 66.7 | 100 |
| Tobramycin | 100 | ||||
| Ertapenem | 0 | ||||
| Imipenem | 75 | 0 | 33.3 | 20 | |
| Meropenem | 0 | 33.3 | 40 | ||
| Cefepime | 100 | 100 | 100 | 80 | |
| Cefotaxime | 100 | 100 | 100 | ||
| Ceftazidime | 100 | 100 | 100 | 60 | |
| Teicoplanin | 7.1 | ||||
| Vancomycin | 0 | ||||
| Clindamycin | 42.9 | ||||
| Daptomycin | 7.7 | ||||
| Erythromycin | 50 | ||||
| Nitrofurantoin | 0 | ||||
| Linezolid | 0 | ||||
| Amoxicillin/clavulanic acid | 100 | 33.3 | 83.3 | 100 | |
| Benzylpenicillin | 100 | ||||
| Oxacillin | 100 | ||||
| Piperacillin/Tazobactam | 20 | 83.3 | |||
| Colistin | 0 | 0 | 50 | 0 | |
| Ciprofloxacin | 91 | 100 | 83.3 | 80 | |
| Levofloxacin | 64.3 | ||||
| Moxifloxacin | 15.4 | ||||
| Trimethoprim/sulfamethoxazole | 14.3 | 75 | 66.7 | 83.3 | 100 |
| Tetracyclin | 28.8 | ||||
| Fosfomycin | 100 | 0 | 66.7 | ||
| Fusidic Acid | 7.1 |
Figure 3Biofilm production of bacterial isolates from patients with chronic skin ulcers. (A) biofilm production of the total bacterial isolates; (B) of MDRO and not-MDRO; (C) of the different bacterial species and according to multidrug resistance profile: (D) MRSA (n = 14) vs. MSSA (n = 23); (E) MDRPA (n = 5) vs. P. aeruginosa (n = 14); (F) K. pneumoniae ESBL (n = 6) vs. K. pneumoniae (n = 4), E. coli ESBL (n = 6) vs. E. coli (n = 9), and A. baumannii (n = 12) compared with the rest of isolates (n = 42). Biofilm formation was assessed by the cBRT and clinical isolates were classified as non-producers, weak, moderate and high biofilm producers. All results expressed as percentage of strains with the specific biofilm-forming ability.